Pletal and Meropenem drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Pletal (cilostazol) and Meropenem (meropenem). Common drug interactions include diabetes mellitus among females and hyperkalaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Pletal and Meropenem. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Pletal?

Pletal has active ingredients of cilostazol. It is often used in blockage of leg arteries. eHealthMe is studying from 6,341 Pletal users. Check the latest studies of Pletal.

What is Meropenem?

Meropenem has active ingredients of meropenem. eHealthMe is studying from 33,295 Meropenem users. Check the latest studies of Meropenem.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 19, 2026

14 people who take Pletal and Meropenem together, and have interactions are studied.

What are the common drug interactions of Pletal and Meropenem, by gender? *:

female:

Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Platelet count decreased
Pseudomonas infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa)
Superinfection

male:

Hyperkalaemia (damage to or disease of the kidney)
Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
Pyrexia (fever)
Somnolence (a state of near-sleep, a strong desire for sleep)
Acute generalised exanthematous pustulosis (acute febrile drug eruption)
Acute respiratory distress syndrome
Alanine aminotransferase increased
Aspartate aminotransferase increased
Blood alkaline phosphatase increased
Blood bilirubin increased

What are the common drug interactions of Pletal and Meropenem, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Hyperkalaemia (damage to or disease of the kidney)

50-59:

n/a

60+:

Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Acute generalised exanthematous pustulosis (acute febrile drug eruption)
Alanine aminotransferase increased
Aspartate aminotransferase increased
Blood alkaline phosphatase increased
Blood bilirubin increased
Blood lactate dehydrogenase increased
Cellulitis (infection under the skin)
Enterocolitis haemorrhagic (bleeding and inflammation of the digestive tract, involving enteritis of the small intestine and colitis of the colon)

What are the existing conditions these people have? *

Diabetes: 5 people, 35.71%
Cellulitis (infection under the skin): 3 people, 21.43%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 3 people, 21.43%
Pneumonia: 3 people, 21.43%
Gastritis (inflammation of stomach): 3 people, 21.43%
Insomnia (sleeplessness): 2 people, 14.29%
Herpes Zoster: 2 people, 14.29%
Arteriosclerosis Of The Extremities (thickening and hardening of arteries- legs and feet): 2 people, 14.29%
Constipation: 2 people, 14.29%
Fever: 2 people, 14.29%

* Approximation only. Some reports may have incomplete information.

Do you take Pletal and Meropenem?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously